My oncologist said the median survival rate for my type of cancer was 6 years. Does that sound right
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
I appreciate you sharing what your oncologist told you. Let me help you understand this in context.
What the Data Shows
According to NCCN Guidelines and American Cancer Society data, median overall survival for HR+/HER2- metastatic breast cancer has improved significantly in recent years—largely due to newer targeted therapies like CDK4/6 inhibitors combined with endocrine therapy.
The range typically cited is 2-5+ years, depending on:
- Which study and time period (older studies show shorter survival; newer ones show longer)
- Whether patients received modern combination therapies
- Individual tumor biology and response to treatment
A 6-year median is actually on the optimistic end of what's commonly reported, which could reflect:
- Your oncologist's experience with their patient population
- Newer treatment protocols at your center
- Optimism based on your specific tumor characteristics
- A particular study or dataset they're referencing
Important Context
"Median" doesn't mean "your" timeline. Here's what median actually means:
- 50% of patients live longer than the median
- 50% live shorter
- Some patients live 10+ years; some less
- Your individual factors (response to treatment, fitness level, access to new therapies) matter enormously
What to Clarify With Your Oncologist
-
"What data or studies are you basing that 6-year estimate on?" (This helps you understand if it's from recent trials or older data)
-
"What factors in my specific case make you optimistic or concerned about that timeline?"
-
"How will we know if treatment is working, and what happens if we need to switch approaches?"
-
"Are there clinical trials or newer therapies I should know about?"
-
"What can I do to optimize my outcomes—exercise, nutrition, monitoring?"
Your oncologist has your complete medical picture and knows the latest data from their institution. These questions will help you understand their reasoning and feel more confident in your treatment plan.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with prognosis for cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2